ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 102 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2014. The put-call ratio across all filers is 0.24 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $62,795,663 | -9.3% | 1,527,875 | +3.1% | 0.02% | -8.3% |
Q1 2024 | $69,216,571 | -8.3% | 1,482,471 | -6.1% | 0.02% | -17.2% |
Q4 2023 | $75,488,795 | +38.2% | 1,578,603 | +3.0% | 0.03% | +26.1% |
Q3 2023 | $54,633,803 | -21.8% | 1,532,505 | +1.2% | 0.02% | -17.9% |
Q2 2023 | $69,830,072 | +21.8% | 1,513,767 | +5.9% | 0.03% | +12.0% |
Q1 2023 | $57,319,501 | -19.7% | 1,429,414 | -7.3% | 0.02% | -21.9% |
Q4 2022 | $71,425,895 | +31.3% | 1,541,677 | +17.4% | 0.03% | +23.1% |
Q3 2022 | $54,393,000 | -26.1% | 1,313,533 | +6.4% | 0.03% | -23.5% |
Q2 2022 | $73,628,000 | -26.2% | 1,234,124 | -10.1% | 0.03% | -10.5% |
Q1 2022 | $99,738,000 | -9.3% | 1,373,429 | +5.0% | 0.04% | -2.6% |
Q4 2021 | $110,003,000 | +5.5% | 1,308,156 | +13.1% | 0.04% | -4.9% |
Q3 2021 | $104,274,000 | -7.5% | 1,156,154 | -2.2% | 0.04% | -8.9% |
Q2 2021 | $112,689,000 | -13.7% | 1,181,847 | +3.0% | 0.04% | -21.1% |
Q1 2021 | $130,647,000 | -20.5% | 1,147,433 | -3.4% | 0.06% | -26.9% |
Q4 2020 | $164,395,000 | +44.8% | 1,187,569 | -14.0% | 0.08% | +27.9% |
Q3 2020 | $113,550,000 | +2.5% | 1,381,552 | -2.4% | 0.06% | -6.2% |
Q2 2020 | $110,736,000 | +76.4% | 1,415,696 | +0.2% | 0.06% | +44.4% |
Q1 2020 | $62,781,000 | -5.0% | 1,413,041 | -8.7% | 0.04% | +18.4% |
Q4 2019 | $66,089,000 | +15.7% | 1,547,393 | +15.8% | 0.04% | +5.6% |
Q3 2019 | $57,144,000 | -22.8% | 1,335,758 | +14.6% | 0.04% | -21.7% |
Q2 2019 | $74,017,000 | -5.6% | 1,165,622 | +3.1% | 0.05% | -9.8% |
Q1 2019 | $78,393,000 | +78.8% | 1,130,232 | +12.1% | 0.05% | +54.5% |
Q4 2018 | $43,838,000 | -42.1% | 1,008,223 | +1.6% | 0.03% | -32.7% |
Q3 2018 | $75,757,000 | +4.6% | 992,357 | +5.4% | 0.05% | -2.0% |
Q2 2018 | $72,401,000 | +58.2% | 941,868 | +5.0% | 0.05% | +51.5% |
Q1 2018 | $45,754,000 | +40.8% | 897,312 | +28.1% | 0.03% | +43.5% |
Q4 2017 | $32,485,000 | -5.3% | 700,406 | +8.7% | 0.02% | -11.5% |
Q3 2017 | $34,315,000 | -19.8% | 644,300 | -6.5% | 0.03% | -21.2% |
Q2 2017 | $42,807,000 | +10.0% | 689,206 | +20.0% | 0.03% | +6.5% |
Q1 2017 | $38,927,000 | -17.2% | 574,309 | -14.1% | 0.03% | -20.5% |
Q4 2016 | $46,985,000 | +7.7% | 668,258 | +8.7% | 0.04% | +5.4% |
Q3 2016 | $43,631,000 | +135.9% | 615,043 | +62.6% | 0.04% | +131.2% |
Q2 2016 | $18,498,000 | -26.3% | 378,195 | -4.6% | 0.02% | -23.8% |
Q1 2016 | $25,105,000 | -42.0% | 396,539 | +2.7% | 0.02% | -43.2% |
Q4 2015 | $43,313,000 | +11.4% | 386,101 | -4.4% | 0.04% | +12.1% |
Q3 2015 | $38,882,000 | +6.3% | 403,717 | +13.1% | 0.03% | +10.0% |
Q2 2015 | $36,562,000 | +93.6% | 357,090 | +17.4% | 0.03% | +100.0% |
Q1 2015 | $18,887,000 | +37.9% | 304,185 | -2.5% | 0.02% | +36.4% |
Q4 2014 | $13,694,000 | -21.7% | 312,073 | +1.0% | 0.01% | -26.7% |
Q3 2014 | $17,490,000 | +27.8% | 309,008 | +1.3% | 0.02% | +25.0% |
Q2 2014 | $13,690,000 | +13.3% | 304,969 | +23.4% | 0.01% | +20.0% |
Q1 2014 | $12,081,000 | – | 247,097 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
First Light Asset Management, LLC | 437,512 | $31,772,000 | 2.80% |
RTW INVESTMENTS, LP | 1,373,284 | $99,728,000 | 2.06% |
Rock Springs Capital Management LP | 1,028,109 | $74,661,000 | 1.88% |
Privium Fund Management B.V. | 112,727 | $8,186,000 | 1.81% |
Avidity Partners Management LP | 869,000 | $63,107,000 | 1.31% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 525,100 | $38,133,000 | 1.16% |
Boxer Capital, LLC | 200,000 | $14,524,000 | 0.75% |
SECTOR GAMMA AS | 46,221 | $3,357,000 | 0.73% |
FEDERATED HERMES, INC. | 3,987,728 | $289,589,000 | 0.65% |
EMERALD ADVISERS, LLC | 223,952 | $16,263,000 | 0.62% |